The following table breaks down the remaining unpaid milestone payments by indication or, in the case of milestones not associated with a specific indication, by triggering events and by involvement of the Company:
| Milestone Payments Involving Performance of Company Obligations |
Milestone Payments Not Involving Performance of Company Obligations |
|||||||
|
Milestones by Indication |
||||||||
|
BPH |
— | $ | 12 million | |||||
|
Prostate cancer |
— | $ | 21 million | |||||
|
Prostatitis and other diseases of the prostate |
— | $ | 21 million | |||||
|
Milestones Not Associated with an Indication |
||||||||
|
Gross sale targets |
— | $ | 8 million | |||||
|
Regulatory approvals |
$ | 5 million | — | |||||